Where Asthma Research Stands Right Now
Asthma affects roughly 25 million people in the United States, and despite the wide availability of inhaled corticosteroids and combination inhalers, a significant portion of patients continue to experience uncontrolled symptoms. The research community has responded by shifting focus toward targeted therapies, particularly biologics that address specific inflammatory pathways rather than applying a one-size-fits-all approach.
Recent years have brought notable developments. The PASSAGE study, conducted across multiple U.S. sites including the University of Michigan and Washington University School of Medicine, examined tezepelumab in a diverse population of patients with severe asthma. Around the same time, a twice-yearly injectable biologic called depemokimab received regulatory clearance for severe eosinophilic asthma in patients aged 12 and older, based on two phase 3 trials that enrolled patients across 331 sites in 23 countries, with a quarter of participants coming from the United States. Meanwhile, the VESTIGE trial demonstrated that dupilumab can reduce mucus buildup in the lungs of patients with moderate-to-severe asthma within four weeks—a finding that matters because mucus obstruction is notoriously difficult to address with standard therapies.
What these studies share is a common thread: researchers are looking beyond symptom control toward modifying the underlying disease process. For someone living with asthma, that shift changes what a clinical trial can offer.
What Kinds of Trials Are Available
Asthma clinical trials fall into several broad categories, and understanding the differences helps narrow your search.
Biologic trials test medications that target specific immune system pathways. These are typically designed for people with moderate-to-severe asthma, particularly those with an eosinophilic or allergic phenotype. The commitment can range from a few months to over a year, with visits scheduled every few weeks or months for injections and monitoring.
Inhaler and combination therapy trials evaluate new delivery devices or fixed-dose combinations of existing medications. A recent example is the approval of Breztri as a triple-combination therapy for asthma in patients 12 and older, supported by the KALOS and LOGOS trials. These studies often appeal to people whose current inhaler regimen is not quite doing enough.
Management and lifestyle trials take a different approach. Instead of testing a new drug, they examine whether behavioral interventions, technology-based tools, or care coordination strategies can improve outcomes. The PRAGMATIC trial in the Bronx, for instance, looked at whether prompting providers to follow guideline-based care could reduce asthma morbidity among urban children.
Observational studies do not involve an experimental treatment at all. Participants continue their usual care while researchers collect data on symptoms, triggers, and lung function over time. These tend to be lower commitment and are a good entry point for someone curious about research but hesitant about trying an unproven therapy.
The table below outlines how these trial types compare in practice.
| Trial Type | What Is Being Studied | Typical Duration | Best Suited For | Key Considerations |
|---|
| Biologic trials | Targeted antibody therapies | 6-52 weeks | Moderate-to-severe asthma, eosinophilic or allergic phenotype | May require regular injections; close monitoring for side effects |
| Inhaler therapy trials | New delivery devices or drug combinations | 12-24 weeks | Mild-to-moderate asthma, suboptimal control on current regimen | Often less invasive; may involve placebo periods |
| Management trials | Behavioral or technology-based interventions | 6-12 months | Any severity level, especially those with frequent exacerbations | No experimental drug exposure; time commitment varies |
| Observational studies | Natural disease progression, triggers | 3-12 months | Anyone with a confirmed asthma diagnosis | No treatment changes; lowest risk profile |
Finding a Trial That Fits
The most comprehensive starting point is ClinicalTrials.gov, a database maintained by the National Library of Medicine. You can search by condition, location, and enrollment status. Typing "asthma" and your city or state will pull up studies recruiting nearby. The site lists eligibility criteria, study design, and contact information for each trial, though the language can be dense. Pay attention to the "recruitment status" field—looking for studies marked "recruiting" or "not yet recruiting" saves time.
Beyond the federal database, several other channels are worth exploring. The American Lung Association operates the Airways Clinical Research Centers network, which conducts asthma trials across the country and often emphasizes studies relevant to underserved populations. The NIH Clinical Center in Bethesda, Maryland, runs its own asthma research program and covers study-related costs for participants. Academic medical centers like the University of Michigan, Washington University, and Mount Sinai in New York regularly recruit for asthma trials, and their websites typically list open studies. Pharmaceutical companies, including Pfizer and AstraZeneca, also maintain trial finders on their websites, though these are limited to their own investigational products.
Karen, a 42-year-old teacher in Ohio, found her trial through her pulmonologist. "I had been on high-dose inhaled steroids for years and still needed prednisone bursts every winter," she recalls. Her doctor mentioned a biologic trial recruiting at the same hospital, and after a screening visit, she was enrolled within three weeks. "The screening was thorough—blood work, lung function tests, a review of my exacerbation history. It took most of a morning, but I walked out with a clear picture of what the next six months would look like."
What Happens After You Express Interest
Once you contact a study team, the process typically moves through several stages. A phone screening usually comes first—a study coordinator asks about your asthma history, current medications, and recent exacerbations to determine if you meet the basic criteria. If you pass that screen, you will be invited for an in-person visit where the team explains the study in detail, including its purpose, procedures, risks, and potential benefits. This is the informed consent process, and you should ask every question on your mind before signing.
After consent, the screening visit involves tests that establish your baseline. Expect spirometry to measure lung function, blood draws to check eosinophil counts and other markers, and possibly allergy testing or imaging. Some trials also require you to keep a symptom diary for a week or two before randomization. There is no guarantee of enrollment after screening—eligibility criteria are strict, and a portion of interested volunteers are not randomized.
For those who do qualify, the trial itself follows a schedule laid out in the protocol. Visits may range from weekly check-ins to quarterly assessments, and between visits, you might be asked to record peak flow readings or complete questionnaires through an app. Miguel, a 29-year-old from Texas who participated in an inhaler trial, describes the routine: "I went to the clinic every month for three months, then every other month after that. Each visit took about 90 minutes. They checked my lung function, asked about any attacks I had, and gave me the study inhaler. Between visits, I logged my symptoms twice a day on my phone. It was manageable with my work schedule."
Costs, Time, and What You Should Know Upfront
Most asthma clinical trials cover study-related medical care, including visits, tests, and the investigational medication. The NIH Clinical Center, for example, does not charge participants for study-related procedures. Many trials also provide compensation for time and travel, though the amount varies widely depending on the study's length and intensity. You should ask about reimbursement during the screening call so there are no surprises.
Travel can be a practical hurdle. Some trials require frequent on-site visits, and if the nearest study site is two hours away, the time commitment adds up. Before committing, map out the clinic location and estimate how many round trips you will need to make. Some sponsors offer transportation assistance or reimburse mileage, but this is not universal.
Insurance is another factor. Study sponsors typically cover the investigational treatment, but your regular asthma medications and any non-study-related care remain your responsibility. Your health insurance should continue to cover your standard prescriptions, and the study team can clarify where the dividing line falls.
One common misconception is that joining a trial means losing access to your regular doctor. In reality, the study team works alongside your existing provider, and you are encouraged to maintain your usual care throughout the trial. The study provides additional monitoring, not a replacement for your pulmonologist or primary care physician.
A few practical steps can make the experience smoother. Keep a folder with your medical records, including recent spirometry results and a list of current medications with dosages—this speeds up the screening process. Bring a notebook to your first visit and write down the names and phone numbers of the study coordinator and principal investigator. And be honest about your symptoms during screening; the criteria exist to protect participants, and overstating or understating your condition does not help anyone.
For those uncertain about committing to an interventional trial, observational studies offer a lower-stakes way to get involved. The NIH asthma phenotyping study, for instance, provides a thorough evaluation of your asthma at no cost while gathering data that helps researchers understand why symptoms persist in some patients. You leave with a detailed characterization of your condition and contribute to the science without changing your treatment.
The American Lung Association's Lung HelpLine (1-800-LUNGUSA) fields questions about research participation and can point you toward trials in your area. ClinicalTrials.gov remains the most exhaustive resource, but talking to a human being often clarifies what a database listing cannot convey—whether a study feels right for your life and your lungs.
研究の知恵